Kornimate/medical-research-clean huggingface dataset:
prevalence of sleep apnea in patients undergoing surgery for colorectal cancer

Conditions: Colorectal Cancer; Sleep Apnea Syndromes; Hypoxia

Summary: 212 patients with colorectal cancer will be investigated before surgery and 100 of them after surgery. 597 individuals from a previous population based study will serve as controls to the prevalence of sleep apnea in the general population. investigations will include polysomonographic sleep apnea recordings during one night, lung function measurements, blood gas samples and questionnaires. controls: men and women from two population-based cohort studies

inclusion: 212 patients with colorectal cancer will be investigated before surgery and 100 of them will also be investigated in the same manner after surgery. due to drop-outs we calculate a need of inviting at least 250 patients. controls: 597 individuals from a previous population based study will serve as controls to the prevalence of sleep apnea in the general population. exclusion: dementia, cpap treated sleep apnea investigations: patients are investigated with lung function, blood-gas samples, questionnaires, overnight polysomnographic sleep apnea recordings including oro-nasal airflow, thoraco-abdominal respiration belts, chin-emg, eog, eeg, ecg (v5) and body position. controls: men and women from two population-based cohort studies the "sleep and health in women" and the "men in uppsala: a study of sleep, apnea and cardiometabolic health" and older men and women from a local senior organization. outcomes: prevalence of sleep apnea and hypoxia, sleep quality, and lung function, blood gas, stop-bang, epworth sleepiness scale, mallampati score, symptoms of sleep apnea, surgical complications, mortality, cancer severity.

Eligibility criteria:
inclusion criteria: * patients scheduled for surgery of colorectal cancer exclusion criteria: * dementia, cpap treatment for obstructive sleep apnea
birth cohort study for respiratory infections

Conditions: Upper Respiratory Tract Infections

Summary: the primary objectives are to evaluate relationship between nasopharyngeal microbial colonization and the occurrence of aom or pneumonia in infants.


Eligibility criteria:
inclusion criteria: * age: 18-35 years * parity: any but with history of previous normal delivery * weight: body mass index greater than 18.5 but less than 35 * past obstetric history: uncomplicated pregnancy, unremarkable medical and obstetric conditions * current pregnancy: uneventful progression of pregnancy * general health: normal health related functional status during pregnancy * singleton pregnancy as determined by clinical examination and/or by ultrasonography * cephalic presentation as determined by abdominal clinical examination * expected to have normal pregnancy related outcome * written informed consent exclusion criteria: * medical history: known history of diabetes, hypertension, or any systemic disorder * gynecological history: history of major gynecological problem/treatment * complications in previous pregnancy * previous obstetric cholestasis * previous acute fatty liver disease * conditions during current pregnancy 1. rhd negative mother 2. aph/placental abruption 3. placenta praevia 4. unstable lie 5. multiple pregnancy 6. pregnancy induced hypertension (systolic \> 140 mm of hg, diastolic \> 90 mm of hg) 7. severe pre-eclampsia or eclampsia 8. gestational diabetes 9. onstetric cholestasis 10. current history of drug/alcohol abuse 11. bmi of less than 18.5 or more than 35. severe pallor as detected clinically or by hb level (\< 7 gm/dl), and oedema 12. blood samples drawn and tested for vdrl (positive vdrl) cephalopelvic disproportion (cpd) 13. history of taking antibiotic within 3 weeks prior to this study 14. patient unwilling to comply with study protocol
comparative study of levonadifloxacin (iv and oral) with linezolid (iv and oral) in acute bacterial skin and skin structure infections (absssi)

Conditions: Acute Bacterial Skin and Skin Structure Infections

Summary: this is a phase iii, multi-center, randomized, active-comparator, study in subjects with absssi. the study has two subgroups for assessment of efficacy and safety - oral subgroup 1 and iv subgroup 2. each subgroup will comprise of two treatment arms.

subjects willing to participate in the study and fulfilling all eligibility criteria will receive either oral therapy (subgroup 1) or iv therapy (subgroup 2). the investigator can initiate treatment with either oral or iv therapy based on clinical judgement i.e subjects who require iv therapy (like subjects with severe absssi or where oral administration is not feasible).

Eligibility criteria:
inclusion criteria: * subjects must be willing to participate in the study and provide a written informed consent * subjects with absssi characterized by any of the following infection types: 1. cellulitis/erysipelas: diffuse skin infection characterized by spreading areas of redness, edema, and/or induration 2. wound infection: an infection characterized by purulent drainage from a wound with surrounding redness, edema, and/or induration 3. major cutaneous abscess: an infection characterized by a collection of pus within the dermis or deeper that is accompanied by redness, edema, and/or induration * subjects with lesion size area of at-least 75 cm2. lesion size will be measured by the area of redness, edema, or induration * subjects with suspected and/or documented evidence of gram-positive infection exclusion criteria: * 1. absssi meeting any of the following criteria: 1. severely impaired arterial blood supply (such that the likelihood of amputation of the infected anatomical site is likely) 2. absssi expected to require more than 10 days of antimicrobial therapy as per the discretion of the investigator 3. subject with suspected or confirmed osteomyelitis or septic arthritis or gangrene 4. absssi requiring surgical intervention (except surgical incision and drainage for abscess) 2. subjects who have received prior antibiotic therapy within past 24 hours for the treatment of current episode of absssi. following are the exceptions to this criteria: 1. subjects who received a single dose of a short-acting antibacterial drug within 24 hours of enrolment 2. subjects with evidence of clinical progression of absssi while on antibacterial drug therapy after at-least 48 hours 3. subjects who received an antibacterial drug for surgical prophylaxis and subsequently develop absssi 3. subjects with current history or diagnosis of hiv, positive test result for hepatitis b surface antigen (hbsag) or hepatitis c virus (hcv) 4. subjects with any clinically significant abnormalities in pulmonary, gastrointestinal, endocrine, hepatic or renal systems
intracervical balloon catheter in the setting of induction of labor for fetal loss or abortion

Conditions: Abortion, Complete; Fetal Death; Induction of Labor Affected Fetus / Newborn

Summary: the goal of this research is to understand whether it is practical and safe to use an intracervical balloon catheter in addition to standard of care medications at the time of an induction of labor for an abortion or fetal death. the medical device used in this study is cleared by the food and drug administration (fda) and is used for induction of labor at term gestational ages (at or above 37 weeks of gestation). the study team will also collect data about patient-level experiences with the procedure, time in labor, and labor-related complications, such as higher-than-expected blood loss or infection.

commonly, induction of labor in the second trimester is accomplished with the use of oral anti-progestin medications (i.e., mifepristone) at least 24 hours prior to administration of sublingual, buccal, or vaginal prostaglandins (e.g., misoprostol). innovation over the past decade has largely been focused on the concomitant use of mechanical dilation for induction of labor in order to reduce the time from initiation of labor to delivery. however, limited data exist to demonstrate the efficacy of an intracervical balloon catheter during second-trimester induction of labor. therefore, the principal investigator seeks to conduct a feasibility randomized controlled trial to evaluate whether an intracervical balloon catheter - commonly used for inductions of labor at later gestational ages - can be used during second-trimester inductions of labor.

Eligibility criteria:
inclusion criteria: * maternal age ≥ 18 * english or spanish-speaking * cervical dilation \< 3 centimeters * gestational age between 22w0d and 27w6d exclusion criteria: * maternal age \< 18 * non-english- or spanish-speaking * cervical dilation ≥ 3 centimeters * gestational age below 22w0d or above 27w6d * allergy to mifepristone or misoprostol * hemolysis, elevated liver enzymes, and low platelets (hellp) syndrome * disseminated intravascular coagulopathy * placenta previa or suspected placenta accreta spectrum disorder * placental abruption * suspected intraamniotic infection * rupture of membranes * untreated genitourinary tract infection * 3 or more cesarean deliveries, classical cesarean delivery, or endometrial cavity-entering myomectomy

Keywords: induction termination medication abortion
efficacy of a stretching protocol for lateral epicondylitis

Conditions: Epicondylitis, Lateral; Elbow Tendinopathy; Epicondylitis of the Elbow; Epicondylitis

Summary: evaluation of the applying a stretching protocol to lateral epicondylitis.

epicondylitis is one of the most common soft tissue disorders of the locomotor system of the upper limb. despite the existence of a large number of therapeutic alternatives for this type of injury, no agreed treatment protocol has been found. some authors even suggest treating the patient from a more global biomechanical perspective. objectives. to evaluate the efficacy of applying a stretching protocol to the entire muscle chain involved in this injury and circumscribed to the entire affected upper limb. methodology. the study will be made up of 40 patients of both genders, randomly distributed in two groups: a control group made up of twenty patients to whom the usual physiotherapy treatment will be applied, and an experimental group made up of the rest of the subjects, in which a stretching protocol will be applied to the whole upper limb affected and defined for this study. the evaluation process will consist of measuring pain perception using a visual analogue scale (vas) and grip strength with a dynamometer. these measurements will be performed on all study subjects before starting treatment, at week 4 and week 6.

Eligibility criteria:
inclusion criteria: * adult subjects over 18 years of age. * clinical diagnosis of lateral epicondylitis made by the rehabilitation physicians collaborating in this study. * patient's prior informed consent for inclusion in the study. exclusion criteria: * patients with significant psychological, neurological and physical impairments that would prevent the recruitment of the information necessary for the research. * patients with significant psychological, neurological and physical alterations that would prevent the application of the treatments necessary for the research. * patients in a situation of legal litigation that could be affected by their participation in this study. * refusal to participate in the study.

Keywords: epicondylitis elbow tendinopathy stretch physiotherapy
bialystok exercise study in diabetes

Conditions: Type 2 Diabetes; PreDiabetes; Overweight; Obesity; Dyslipidemias

Summary: the "bialystok exercise study in diabetes" (besd), is an exercise intervention study, conducted by the department of endocrinology, diabetology and internal medicine and clinical research centre of the medical university of bialystok. in the project, sedentary males at different stages of dysglycemia living in the city of bialystok participate in three months of an exercise intervention consisting of supervised training sessions at a local fitness centre. the aim of the study is to assess the effectiveness of the exercise intervention in patients at different stages of dysglycemia progression, including type 2 diabetes and prediabetes and compare the response between groups.


Eligibility criteria:
inclusion criteria: * age: 35-65 years old * bmi: 25-35 kg/m2 * male gender * ability of performing exercise trainings * sedentary lifestyle exclusion criteria: * smoking * drug or alcohol addiction * any chronic disease (exceptions: hypertension, obesity with bmi ≤ 35 kg/m2, type 2 diabetes) * any chronic medications (exceptions: angiotensin-converting-enzyme inhibitors for hypertension and metformin in type 2 diabetics) * highly active lifestyle * medical contraindications to participate in planned exercise sessions

Keywords: exercise intervention type 2 diabetes prevention type 2 diabetes treatment prediabetes behavioural intervention
a phase ii study of ara-c (cytarabine) in men with androgen independent prostate cancer

Conditions: Prostate Cancer

Summary: this is a single-arm, open label phase ii trial of the investigational agent, ara-c (cytarabine), in patients diagnosed with hormone refractory prostate cancer whose disease has progressed on or deemed not suitable for standard chemotherapy with docetaxel. ara-c appears to inhibit dna synthesis and is cytotoxic to a wide variety of mammalian cells. recent discoveries have suggested the role of gene fusions in the ets family of transcription factors as important for the development of prostate cancer. ara-c appears to block ets genes, suggesting that it is worthwhile to explore ara-c as a potential new treatment for patients with hormone refractory prostate cancer given that there is no standard of care for the proposed patient population. in this study, ara-c will be administered intravenously for 2 days every 3 weeks (1 cycle). treatment will be for 6 cycles if tolerated and may be continued in patients who are responding and do not have severe toxicity.


Eligibility criteria:
inclusion criteria: * biopsy-proven prostate cancer or clinical picture consistent with metastatic prostate cancer with high level of serum psa (\> 20ng/ml) * at least 4 weeks after docetaxel treatment and have at least 2 consecutive rising psas measured at least 2 weeks apart * progression on or intolerance of docetaxel chemotherapy * ecog performance status ≤ 2 * adequate organ and marrow function exclusion criteria: * prior treatment with cytarabine * receiving any other investigational or anticancer agents * uncontrolled intercurrent illness * active malignancy at any other site excluding squamous cell or basal cell carcinomas of the skin * radiotherapy within the past 4 weeks

Keywords: prostate androgen independent phase ii second line androgen-independent prostate cancer
clinical and radiological outcomes of oblique lateral lumbar interbody fusion

Conditions: Degenerative Disc Disease; Spondylolisthesis; Lumbar Disc Herniation

Summary: this study is undertaken to evaluate the outcomes of oblique lateral lumbar interbody fusion (ollif). specifically, the study seeks to measure outcomes on radiological imaging, outcomes reported by the patients on standardized questionnaires, and complication rates.


Eligibility criteria:
inclusion criteria: * clinical diagnosis, confirmed by imaging, of one of the following conditions: severe degenerative disc disease, spondylolisthesis, spinal stenosis, disc herniation * completion of a full course of conservative therapy. conservative therapy may include physical therapy, therapeutic injections, bracing and behavioral modification. exclusion criteria: * bony obstruction of the approach * significant spinal canal stenosis * large facet hypertrophy * grade ii listhesis * scoliosis with cobb angle \> 10º * patients who underwent procedures that were converted to open fusions

Keywords: degenerative disk disease lumbar fusion minimally invasive surgery lumbar disk disease
low-volume polyethylene glycol bowel preparation for colonoscopy

Conditions: Bowel Preparation for Colonoscopy

Summary: the efficacy and tolerability of a low-volume (2 l) peg regimen for colonoscopy compared to single (4 l) or split-dose (2 l + 2 l) treatments are not different.

in-hospital patients were randomly assigned to one of three groups: group 1 single dose (peg-3350; peg-4 l the day previous of the study, starting at 17:00 and finishing at 21:00 h); group 2: split-dose (peg-3350; 2 l the day before 17:00-19:00 h and 2 l same day of the procedure 06:00-08:00 am); group 3: low-volume 2 l peg-solution (same day of the procedure 06:00-08:00 am). the quality of colonic preparation was assessed by the boston bowel preparation scale (13); tolerability (nausea, vomiting, and abdominal pain), compliance, sleep disturbance and adverse effects in group 3 were compared with those in groups 1 and 2. the time since the last dose of bowel-preparation agent, the time since the last solid food was consumed, the approximate amount of bowel preparation taken (0%, 25%, 75%, or 100%), and the start time of the colonoscopy were recorded. satisfactory colon preparation was considered when scores of the boston bowel preparation scale were 2/3; otherwise, the procedure was considered unsatisfactory preparation.

Eligibility criteria:
inclusion criteria: * in-hospital patients with an indication for colonoscopy exclusion criteria: * patients under 18 years of age * the presence of a severe illness (cardiac, renal, or metabolic) * major psychiatric illness * known allergies to peg-3350 * refusal to consent to the study

Keywords: colonoscopy preparation polyp polyethylene glycol
early prevention of preeclampsia study

Conditions: Preeclampsia

Summary: this is a randomized controlled trial to estimate the efficacy of low dose aspirin for preventing preeclampsia in women identified as high risk. the investigators hypothesize that the risk of preeclampsia in women identified by a first trimester multiparameter predictive model to be at high risk will be significantly reduced by initiating low dose aspirin early in pregnancy.

this will be a randomized control trial to estimate the efficacy of low dose aspirin in preventing preeclampsia in women identified in the first trimester to be at high risk. we will also obtain maternal blood, cord blood and placenta specimen for basic science studies to attempt to dissect biological mechanisms of aspirin effects. in addition we will conduct a cost-benefit analysis to determine the cost effectiveness of screening and using aspirin prophylaxis for screen positive women. rationale for design: the randomized control trial is the 'gold standard' of research design. other designs such as case-control, retrospective cohort and prospective cohort are limited by potential bias and confounding. randomly assigning subjects to different interventions minimizes selection bias. the random assignment also results in groups that are likely to be similar with regards to important confounding variables. this minimizes confounding by both measured and unmeasured factors. while random allocation does not guarantee the groups will be identical, it does ensure that any differences between them are due to chance alone. finally, randomization produces groups that are random samples of the population. this permits use of standard statistical tests that are based on probability theory.

Eligibility criteria:
inclusion criteria: * singleton pregnancy undergoing ultrasound examination at 9 0/7 - 14 6/7 weeks * any one or more factors identified as high risk from the identified risk factors: chronic hypertension, prepregnancy diabetes mellitus, previous preeclampsia, obesity (bmi \>30), bilateral uterine artery notches preeclampsia risk score greater than 6, low papp-a ( \< 0.52 mom) exclusion criteria: * multiple gestations, * fetal aneuploidy * major fetal structural anomaly * bleeding disorder * allergy to aspirin * women already on aspirin or heparin.

Keywords: preeclampsia aspirin
clinical study of bilateral decompression with interbody fusion for spondylolisthesis

Conditions: Lumbar Spondylolisthesis

Summary: laminectomy with plif has been shown to achieve satisfactory clinical outcomes, but it leads to potential adverse consequences associated with extensive disruption of posterior bony and soft-tissue structures. the investigators plan to compare the clinical and radiographic outcomes of bilateral decompression with transforaminal lumbar interbody fusion and laminectomy with posterior lumbar interbody fusion in the treatment of degenerative spondylolisthesis.


Eligibility criteria:
inclusion criteria: 1. lumbar spondylolisthesis 2. symptoms of low back pain and/or neurogenic claudication with or without radiculopathy referable to the lumbar spine, 3. at least 3 months of failed conservative therapies exclusion criteria: 1. multilevel lumbar degenerative diseases 2. history of previous lumbar surgery
assessment of endothelial function, apolipoproteins and adiponectin

Conditions: Cirrhosis

Summary: the overall hypothesis is that endothelial function, apolipoprotein levels and adiponectin levels are accurate predictors of underlying cardiovascular disease in patients with end-stage liver disease, in whom standard tools for the diagnosis of and screening for cardiovascular disease are of limited utility.

this study is looking at using a noninvasive test called a reactive hyperemia peripheral artery tonometry (rh-pat) to check endothelial dysfunction. endothelial dysfunction is thought to be an indication of future heart disease or metabolic disorders. adiponectin is a hormone associated with heart disease. apolipoprotein levels, are established risk factors for coronary artery disease in the general population. our group would like to see if there is a link between endothelial function, adiponectin, apolipoprotein levels and posttransplant heart disease complications. the study would be taking these results to find new clinical procedures for patients that are at potentially higher risk of heart problems during and after their liver transplant procedure.

Eligibility criteria:
inclusion criteria: * greater than or equal to 21 years of age. * cirrhotic end-stage liver disease * pre-transplant exclusion criteria: * dialysis shunt * non-cirrhotic liver disease * fulminant hepatic failure

Keywords: liver transplant end-stage liver disease cirrhosis
the effect of adding metformin to the treatment of hepatitis c

Conditions: Hepatitis C

Summary: insulin resistance is known to adversely effect viral response to treatment in hepatitis c patients we are aiming to study the effect of an insulin sensitizer, metformin, in viral response of hepatitis c to treatment with pegylated interferon and ribavirin in a double blind randomized controlled trial

subjects with hepatitis c will be randomized to receive standard treatment with or without metformin. the results will be compared.

Eligibility criteria:
inclusion criteria: * chronic hepatitis c * iranian nationality * treatment naive exclusion criteria: * cirrhosis * diabetes mellitus * hbv/hiv coinfection * contraindications of metformin, interferon, ribavirin * severe medical conditions (e.g. chf, crf, psychosis, ...) * not consenting

Keywords: hepatitis c metformin insulin resistance
systems biology of amyotrophic lateral sclerosis (als)

Conditions: ALS; ALS (Amyotrophic Lateral Sclerosis)

Summary: the goal of this observational study is to identify molecular features in multiple clinical samples and/or the patient environment that are associated with als. participants will collect biological samples and answer questionnaires regarding their health at each appointment with their als practitioner.


Eligibility criteria:
inclusion criteria: * patient of dr. espíndola at ufsc exclusion criteria: -